Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 416 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control cream Clear all
Completed Not applicable Interventional

Human Milk Cream as a Caloric Supplement in Pre-Term Infants

NCT01487928
View directory record Official record
Conditions
Prematurity
Interventions
Human Milk Cream
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Days
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 25, 2026, 1:10 AM EDT
Terminated Not applicable Interventional Results available

Adjunctive Transcranial Direct Current Stimulation

NCT02665988
View directory record Official record
Conditions
Chronic Pain, Psychiatric Disorders
Interventions
tDCS, Sham tDCS
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream

NCT05514353
View directory record Official record
Conditions
Healthy Volunteers, Psoriasis
Interventions
PBI-100 Topical Cream, Vehicle Cream
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Peanuts and Glycemic Control

NCT03654651
View directory record Official record
Conditions
Type2 Diabetes, Cardiovascular Diseases
Interventions
Peanut, High carbohydrate snack
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

NCT02566369
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 (trifarotene) 50μg/g cream, Placebo cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
86
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

NCT05078827
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
Drug
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 25, 2026, 1:10 AM EDT
Withdrawn Phase 1 Interventional

Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival

NCT01960764
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Pre-Treatment with Dial liquid antibacterial soap, Control
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream

NCT02918617
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Control toothpaste containing Novamin® technology, Control toothpaste containing 1500 ppm fluoride as MFP, Test toothpaste with nano-HAP (high concentration), Test toothpaste with nano-HAP (low concentration), Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3, Control toothpaste without nano-HAP, Test toothpaste with nano-HAP (medium concentration), Test cream with nano-HAP (higher concentration), Control cream without nano-HAP
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

NCT02014376
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

NCT03850483
View directory record Official record
Conditions
Psoriasis
Interventions
PF-06700841, Vehicle (Placebo)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 1 Interventional

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

NCT06733402
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)

NCT00076375
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Nanocrystalline silver cream (NPI)
Drug
Lead sponsor
Nucryst Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Huntsville, Alabama • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

NCT05119920
View directory record Official record
Conditions
Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions
Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
19
States / cities
Chandler, Arizona • Sun City, Arizona • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

NCT03210740
View directory record Official record
Conditions
Actinic Keratosis
Interventions
AM001 Cream, 7.5%, Vehicle Cream
Drug
Lead sponsor
AmDerma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 25, 2026, 1:10 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Lidocaine-Prilocaine Cream in Conjunction With Paracervical Block for Pain With Abortion

NCT03508804
View directory record Official record
Conditions
Pain
Interventions
Lidocaine-Prilocaine Cream, Placebo Cream, 1% Lidocaine Paracervical Block
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 25, 2026, 1:10 AM EDT
Terminated Phase 4 Interventional Results available

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

NCT00669071
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, Cetaphil® Moisturizing Cream as Inactive Control
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
La Jolla, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

NCT00948428
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod, Aldara™, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Hot Springs, Arkansas • Fresno, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

NCT05579899
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
EVO101
Drug
Lead sponsor
Evommune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 25, 2026, 1:10 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)

NCT02213757
View directory record Official record
Conditions
Microscopic Hematuria
Interventions
Premarin vaginal estrogen cream, Placebo vaginal cream
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 25, 2026, 1:10 AM EDT
Completed No phase listed Observational

Cutaneous Lupus Medication Experience Study

NCT02176148
View directory record Official record
Conditions
Cutaneous Lupus
Interventions
fluocinonide 0.05% cream
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

NCT02871479
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
SAN007 5% cream, Placebo, SAN007 10% cream
Drug
Lead sponsor
Santalis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Austin, Texas • Bryan, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 3 Interventional

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT02896101
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00674739
View directory record Official record
Conditions
Genital Warts
Interventions
Imiquimod, 3.75% imiquimod cream, placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 25, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris

NCT00673933
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Methyl aminolevulinate (MAL) PDT
Drug
Lead sponsor
Photocure
Industry
Eligibility
15 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Naperville, Illinois • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 25, 2026, 1:10 AM EDT